Actinium Pharmaceuticals(ATNM) - 2024 Q4 - Annual Report

☒ Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Exact name of registrant as specified in its charter) | Delaware | 74-2963609 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | 100 Park Ave., 23 Floor For the fiscal year ended December 31, 2024 New York, NY 10017 or ☐ Transition Report Pursuant To Sec ...